Loading…
NEUROONE MEDICAL TECHNOLOGIES Corp
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Major managers that reported this stock in their latest 13F.
None of the investors we track reported a position in NMTC.
▼ -92.1% over 5Y.
today you would have $56.12▼ -94.4%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
The last 7 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Year-end price | $4.55 | $4.96 | $9.48 | $7.20 | $11.64 | $28.26 | $42.84 | |
| P/S | 19.4x | 4.2x | 7.4x | 19.4x | 113.8x | 176.3x | — | — |
| P/B | 5.7x | 5.4x | 31.0x | 6.1x | 2.0x | 4.8x | 17.5x | — |
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| SCNXScienture Holdings, Inc. | $0.39 | — | 0.3x | — | -53.47% | $16.18M |
| ADVBAdvanced Biomed Inc. | $9.70 | 2.4x | 1.5x | — | 71.33% | $16.03M |
| MDCXMedicus Pharma Ltd. | $0.26 | — | — | — | -7446.11% | $16.28M |
| NRSNNeuroSense Therapeutics Ltd. | $0.42 |
NeuroOne Medical Technologies Corporation, a medical technology company, provides solutions for continuous electroencephalogram (cEEG) and stereoelectrocencephalography (sEEG) recording in the United States. The company also provides solutions for spinal cord stimulation, brain stimulation, drug delivery and ablation solutions for patients suffering from epilepsy, trigeminal neuralgia, Parkinson's disease, dystonia, essential tremors, and chronic pain due to failed back surgeries and other pain-related neurological disorders. The company has a collaboration with the Department of Neurology's Division of Epilepsy at the University of Minnesota Medical School to advance a study evaluating epilepsy therapies. The company is based in Eden Prairie, Minnesota.
Company description provided by Yahoo Finance.
| EPS |
| -$0.54 |
| -$2.76 |
| -$3.90 |
| -$3.78 |
| -$5.58 |
| -$15.12 |
| -$10.26 |
| Profit margin | -607.42% | -39.63% | -356.74% | -607.42% | -5841.95% | -5584.28% | — | — |
| ROE | -170.78% | -50.98% | -1498.53% | -189.77% | -104.12% | -151.79% | -660.17% | — |
Median, not average: a single year of near-zero profit produces a P/E of 400 and would drag an average on its own. P/E years above 200x are left out, the same cut the fair price uses — so this median matches the “its own history” method below. Price and EPS have no median: they are series that grow.
| — |
| — |
| — |
| -2174.98% |
| $15.88M |
| ADILAdial Pharmaceuticals Inc | $5.60 | — | — | — | -2011.64% | $16.43M |
| PLURPluri Inc. | $1.53 | — | — | — | — | $16.51M |